Aura Biosciences/AURA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Aura Biosciences

Aura Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing precision immunotherapies to treat solid tumors designed to preserve the function of the afflicted organ with cancer. It is developing a pipeline of virus-like drug conjugates (VDCs), a class of drugs with a dual mechanism of action, that promote cancer cell death by both the delivery of the cytotoxic payload to generate acute necrosis and activation of a secondary immune mediated response. Its lead candidate, bel-sar, is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. Bel-sar consists of a human papillomavirus (HPV)-derived virus-like particle (VLP), conjugated to hundreds of infrared laser-activated molecules. It is evaluating the bel-sar in a Phase III CoMpass trial for the first line treatment of early-stage choroidal melanoma.

Ticker

AURA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Elisabet de los Pinos

Employees

88

Headquarters

Boston, United States

Aura Biosciences Metrics

BasicAdvanced
$364M
Market cap
-
P/E ratio
-$1.86
EPS
-
Beta
-
Dividend rate
$364M
$13.50
$5.99
204K
21.965
-35.66%
-40.43%
-37.16%
1.743
1.744
6.09%

What the Analysts think about Aura Biosciences

Analyst Ratings

Majority rating from 6 analysts.
Buy

Aura Biosciences Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$20M
-10.86%
Profit margin
0.00%
NaN%

Aura Biosciences Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 17.73%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.48
-$0.48
-$0.56
-$0.40
-
Expected
-$0.49
-$0.52
-$0.41
-$0.49
-$0.45
Surprise
-1.96%
-7.83%
35.86%
-17.73%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Aura Biosciences stock?

Aura Biosciences (AURA) has a market cap of $364M as of June 19, 2024.

What is the P/E ratio for Aura Biosciences stock?

The price to earnings (P/E) ratio for Aura Biosciences (AURA) stock is 0 as of June 19, 2024.

Does Aura Biosciences stock pay dividends?

No, Aura Biosciences (AURA) stock does not pay dividends to its shareholders as of June 19, 2024.

When is the next Aura Biosciences dividend payment date?

Aura Biosciences (AURA) stock does not pay dividends to its shareholders.

What is the beta indicator for Aura Biosciences?

Aura Biosciences (AURA) does not currently have a Beta indicator.

What is the Aura Biosciences stock price target?

The target price for Aura Biosciences (AURA) stock is $19.8, which is NaN% below the current price of $. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Aura Biosciences stock

Buy or sell Aura Biosciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing